Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease
Trevor L. Schell, Keith L. Knutson, Sumona Saha, et al.
Inflammatory Bowel Diseases (2022) Vol. 28, Iss. 11, pp. 1781-1786
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis
Anuraag Jena, Deepak James, Anupam Singh, et al.
Clinical Gastroenterology and Hepatology (2022) Vol. 20, Iss. 7, pp. 1456-1479.e18
Open Access | Times Cited: 63
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
James L. Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 11, pp. 1005-1015
Open Access | Times Cited: 50
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic
Nicholas A. Kennedy, Malik Janjua, Neil Chanchlani, et al.
Gut (2022) Vol. 72, Iss. 2, pp. 295-305
Open Access | Times Cited: 37
Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic
Simeng Lin, Louis Ho Shing Lau, Neil Chanchlani, et al.
Gut (2022) Vol. 71, Iss. 7, pp. 1426-1439
Open Access | Times Cited: 25
Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety
Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Sen Hee Tay
Vaccines (2022) Vol. 10, Iss. 5, pp. 668-668
Open Access | Times Cited: 18
Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination
Freddy Caldera, Francis A. Farraye, Brian M. Necela, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 8, pp. 1202-1209
Open Access | Times Cited: 17
Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease
Freddy Caldera, Luke J. Richard, Mazen Almasry, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. 1662-1666
Open Access | Times Cited: 8
Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments
Eva Zhang, Thi H. O. Nguyen, Lilith F. Allen, et al.
Gut (2023), pp. gutjnl-329136
Open Access | Times Cited: 8
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.
Trevor L. Schell, Freddy Caldera
PubMed (2024) Vol. 20, Iss. 2, pp. 88-97
Closed Access | Times Cited: 2
COVID-19 Vaccination in Inflammatory Bowel Disease (IBD)
Aleksandra Kubas, Ewa Małecka‐Panas
Journal of Clinical Medicine (2022) Vol. 11, Iss. 9, pp. 2676-2676
Open Access | Times Cited: 13
Systemic and T cell‐associated responses to SARS‐CoV‐2 immunisation in gut inflammation (STAR SIGN study): effects of biologics on vaccination efficacy of the third dose of mRNA vaccines against SARS‐CoV‐2
Simon Woelfel, Joel Dütschler, Marius König, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 57, Iss. 1, pp. 103-116
Open Access | Times Cited: 13
Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]
Jayne Doherty, Neil O’Moráin, Róisín Stack, et al.
Journal of Crohn s and Colitis (2023) Vol. 17, Iss. 9, pp. 1445-1456
Open Access | Times Cited: 4
Additional COVID-19 Booster Doses Increase Anti-spike Serum Antibody Concentrations Among Patients With Inflammatory Bowel Disease
Trevor L. Schell, Oscar M. Ramirez, Mazen Almasry, et al.
Inflammatory Bowel Diseases (2023) Vol. 29, Iss. 10, pp. e38-e39
Open Access | Times Cited: 2
COVID-19 vaccination in adults with inflammatory bowel disease
Megan Lutz, Sarah Lazarus, Freddy Caldera
Therapeutic Advances in Gastroenterology (2023) Vol. 16, pp. 175628482311731-175628482311731
Open Access | Times Cited: 2
Higher and Sustained Cell-Mediated Immune Responses after Three Doses of mRNA COVID-19 Vaccine In Patients with Inflammatory Bowel Disease on Anti-TNF Therapy
Freddy Caldera, Stacey Rolak, Francis A. Farraye, et al.
Clinical and Translational Gastroenterology (2024)
Open Access
SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection
Alice Hoyois, C Gulkilik, Leila Mekkaoui, et al.
Acta Gastro Enterologica Belgica (2024) Vol. 87, Iss. 2, pp. 263-273
Closed Access
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, et al.
Gastroenterología y Hepatología (English Edition) (2024) Vol. 47, Iss. 8, pp. 821-833
Closed Access
Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Vítor Macedo Silva, Tiago Lima Capela, Marta Freitas, et al.
Inflammatory Bowel Diseases (2022) Vol. 29, Iss. 2, pp. 268-273
Open Access | Times Cited: 3
COVID-19 Vaccination Among Individuals With Inflammatory Bowel Disease: Perception, Efficacy, and Safety.
Kimberly N. Weaver, Michael D. Kappelman, Millie D. Long
Carolina Digital Repository (University of North Carolina at Chapel Hill) (2022) Vol. 18, Iss. 7, pp. 388-399
Open Access | Times Cited: 3
An Updated Comparative Study on the Impact of COVID-19 Infection and Vaccination in Patients with Inflammatory Bowel Disease and Irritable Bowel Syndrome
Nicole Sciberras, Anthea Pisani, Vanessa Vella, et al.
Journal of Gastrointestinal and Liver Diseases (2022) Vol. 31, Iss. 4, pp. 424-428
Open Access | Times Cited: 3
Impact of Anti-TNFα Treatment on the Humoral Response to the BNT162b2 mRNA COVID-19 Vaccine in Pediatric Inflammatory Bowel Disease Patients
Kosuke Kashiwagi, Keisuke Jimbo, Mitsuyoshi Suzuki, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1618-1618
Open Access | Times Cited: 2
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study
Ali Al‐Janabi, Amelle Ra, Zoe Littlewood, et al.
British Journal of Dermatology (2022) Vol. 188, Iss. 4, pp. 542-551
Closed Access | Times Cited: 1
Managing IBD in the COVID-19 era
Nicholas Scalzo, Ryan C. Ungaro
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access
Antibody Kinetics after Three Doses of SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease
Evangelos Tsipotis, Ankith Maremanda, Laura B. Zeiser, et al.
Medicina (2023) Vol. 59, Iss. 8, pp. 1487-1487
Open Access
Humoral Immunity in Immunosuppressed IBD Patients after the Third SARS-CoV-2 Vaccination: A Comparison with Healthy Control Subjects
Richard Vollenberg, Eva U. Lorentzen, Joachim Kühn, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1411-1411
Open Access
Page 1 - Next Page

Scroll to top